New nanopharmaceutical may help overcome resistance to specific anticancer drugs

Conclusions: Results generated through this translational research plan suggest that CRLX101 can overcome HIF-1α-mediated acquired resistance to antiangiogenic drugs, assisting the use of CRLX101 in combination with antiangiogenic medicines as an exciting new paradigm for the treatment of cancer. Related Posts:Cleveland Clinic’s preventive breast cancer vaccine…Harvard Stem Cell Institute publishes initial clinical trialImportant advance in the fight against skin cancerNew IBS treatment shows possible in Phase 2 researchNew blood test could help millions of patients with…The post New nanopharmaceutical may help overcome resistance to specific anticancer drugs appeared first on My Irritable Bowel Syndrome Story.
Source: My Irritable Bowel Syndrome Story - Category: Other Conditions Authors: Tags: IBS News Source Type: blogs